ALLIANCES AND COLLABORATIONS (Sanofi) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended		9 Months Ended				3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended	3 Months Ended		9 Months Ended			3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Sep. 30, 2013 Avapro Avalide [Member]	Sep. 30, 2012 Avapro Avalide [Member]	Sep. 30, 2013 Avapro Avalide [Member]	Sep. 30, 2012 Avapro Avalide [Member]	Sep. 30, 2013 Sanofi [Member] Avapro Avalide [Member] Active Pharmaceutical Ingredient Supply Arrangements [Member]	Sep. 30, 2012 Sanofi [Member] Avapro Avalide [Member] Active Pharmaceutical Ingredient Supply Arrangements [Member]	Sep. 30, 2013 Sanofi [Member] Avapro Avalide [Member] Active Pharmaceutical Ingredient Supply Arrangements [Member]	Sep. 30, 2012 Sanofi [Member] Avapro Avalide [Member] Active Pharmaceutical Ingredient Supply Arrangements [Member]	Sep. 30, 2013 Sanofi [Member] Avapro, Avalide, and Plavix [Member]	Sep. 30, 2012 Sanofi [Member] Avapro, Avalide, and Plavix [Member]	Sep. 30, 2013 Sanofi [Member] Avapro, Avalide, and Plavix [Member]	Sep. 30, 2012 Sanofi [Member] Avapro, Avalide, and Plavix [Member]	Dec. 31, 2018 Sanofi [Member] Avapro, Avalide, and Plavix [Member]	Sep. 30, 2013 Sanofi [Member] Territory Covering Americas and Australia [Member] Avapro, Avalide, and Plavix [Member]	Sep. 30, 2012 Sanofi [Member] Territory Covering Americas and Australia [Member] Avapro, Avalide, and Plavix [Member]	Sep. 30, 2013 Sanofi [Member] Territory Covering Americas and Australia [Member] Avapro, Avalide, and Plavix [Member]	Sep. 30, 2012 Sanofi [Member] Territory Covering Americas and Australia [Member] Avapro, Avalide, and Plavix [Member]	Dec. 31, 2012 Sanofi [Member] Territory Covering Americas and Australia [Member] Avapro, Avalide, and Plavix [Member]	Sep. 30, 2013 Sanofi [Member] Territory Covering Europe and Asia [Member] Avapro, Avalide, and Plavix [Member]	Sep. 30, 2012 Sanofi [Member] Territory Covering Europe and Asia [Member] Avapro, Avalide, and Plavix [Member]	Sep. 30, 2013 Sanofi [Member] Territory Covering Europe and Asia [Member] Avapro, Avalide, and Plavix [Member]	Sep. 30, 2012 Sanofi [Member] Territory Covering Europe and Asia [Member] Avapro, Avalide, and Plavix [Member]	Dec. 31, 2012 Sanofi [Member] Territory Covering Europe and Asia [Member] Avapro, Avalide, and Plavix [Member]
Alliances and Collaborations Statement [Line Items]
Payment from Sanofi related to restructuring of the alliance agreement																			$ 200
Royalty revenue															53		160
Previously deferred profit recognized upon restructuring of an alliance agreement																											22
Controlling interest ownership percentage																				50.10%		50.10%			50.10%		50.10%
Equity method investment ownership percentage																									49.90%		49.90%
Noncontrolling interest ownership percentage																				49.90%		49.90%
Net Sales	4,065	3,736	11,944	13,430			71	95	173	419	43	29	94	97	113	159	350	2,917
Royalties - Cost of products sold																19	2	527
Equity in net income of affiliates	(42)	(40)	(128)	(150)																					(46)	(45)	(140)	(163)
Other (income)/expense	5	(11)	185	(246)												(61)	(14)	(122)
Noncontrolling interest - pre-tax															(4)	(7)	19	847
Distributions (to)/from Sanofi - Noncontrolling interest			(46)	(765)																(11)	290	(33)	(768)
Distributions from Sanofi - Investment in affiliates																									51	54	103	183
Investment in affiliates																									46		46		9
Noncontrolling interest	(12)		(12)		15	(89)														(44)		(44)		(30)
Net sales																									111	248	288	886
Gross profit																									91	132	232	402
Net income																									$ 90	$ 116	$ 228	$ 358